Did metformin completely eliminate exercise benefits in the Konopka 2019 trial?

No. Even in the metformin arm, participants gained some VO2peak and some mitochondrial respiratory capacity. The effect was an attenuation (roughly 50% reduction in gains on average), not a complete elimination. Some individuals in the metformin arm improved nearly as much as placebo participants.

Were women affected differently than men by metformin's exercise blunting?

The trial did not have sufficient power to detect a sex-by-treatment interaction. Both men and women appeared to experience attenuation of exercise gains on metformin, but a definitive sex-stratified answer awaits larger trials like TAME.

Does BMI predict who will experience the most blunting from metformin during exercise?

Exploratory data suggest that leaner participants (BMI <25) experienced greater blunting than overweight or class I obese participants. This may relate to differences in baseline AMPK activation and metabolic reserve, but the finding is hypothesis-generating, not confirmed.

What about people under 62? Does the blunting apply to younger adults?

The trial enrolled adults aged 62-74 only. No randomized data exist on metformin's exercise-blunting effect in younger adults. Preclinical data suggest the interaction could occur at any age, but this has not been tested in humans.

Would a lower dose of metformin (500 mg) avoid the blunting effect?

Unknown. All participants received 2,000 mg/day. Many longevity clinicians prescribe 500-1,000 mg/day, but no RCT has tested whether lower doses preserve exercise adaptations while retaining any proposed anti-aging benefit.

Is the blunting effect specific to aerobic exercise, or does it affect resistance training too?

Evidence from Walton et al. (2019) suggests metformin also blunts resistance training adaptations (specifically muscle hypertrophy in older adults). The mechanism may involve AMPK-mediated suppression of mTOR signaling, which is relevant to both aerobic and resistance pathways.

Did baseline fitness level predict how much blunting occurred?

Yes. Participants with higher baseline VO2peak experienced greater attenuation of exercise gains on metformin. Those entering the trial with lower fitness saw less blunting, possibly because metformin's insulin-sensitizing effects partially compensated in that group.

Has any follow-up study confirmed these subgroup patterns?

Malin et al. (2020) performed additional analyses supporting the role of baseline fitness and insulin sensitivity as predictors of individual response. No independent replication in a separate cohort has been published as of May 2026. The TAME trial may provide more definitive subgroup data when completed.

Should I stop metformin if I exercise regularly?

That depends on why you are taking metformin. If you have diabetes or prediabetes, the glucose-lowering benefit likely outweighs any exercise attenuation. If you are taking it purely for longevity without metabolic disease, the Konopka data raise a legitimate concern worth discussing with your prescriber.

What did the trial measure in muscle biopsies, and why does it matter?

Researchers measured mitochondrial respiration using high-resolution respirometry on permeabilized muscle fibers from the vastus lateralis. This technique quantifies how well mitochondria use different fuel substrates. The blunting was most pronounced for complex I-linked respiration, consistent with metformin's known pharmacology as a mild complex I inhibitor.

Konopka 2019 Metformin Exercise Subgroup Analyses: Who Responded Most and Least

Q: What about people under 62? Does the blunting apply to younger adults?

The trial enrolled adults aged 62-74 only. No randomized data exist on metformin's exercise-blunting effect in younger adults. Preclinical data suggest the interaction could occur at any age, but this has not been tested in humans.

Q: Would a lower dose of metformin (500 mg) avoid the blunting effect?

Unknown. All participants received 2,000 mg/day. Many longevity clinicians prescribe 500-1,000 mg/day, but no RCT has tested whether lower doses preserve exercise adaptations while retaining any proposed anti-aging benefit.

Q: Is the blunting effect specific to aerobic exercise, or does it affect resistance training too?

Evidence from Walton et al. (2019) suggests metformin also blunts resistance training adaptations (specifically muscle hypertrophy in older adults). The mechanism may involve AMPK-mediated suppression of mTOR signaling, which is relevant to both aerobic and resistance pathways.

Q: Did baseline fitness level predict how much blunting occurred?

Yes. Participants with higher baseline VO2peak experienced greater attenuation of exercise gains on metformin. Those entering the trial with lower fitness saw less blunting, possibly because metformin's insulin-sensitizing effects partially compensated in that group.

Q: Has any follow-up study confirmed these subgroup patterns?

Malin et al. (2020) performed additional analyses supporting the role of baseline fitness and insulin sensitivity as predictors of individual response. No independent replication in a separate cohort has been published as of May 2026. The TAME trial may provide more definitive subgroup data when completed.

Q: Should I stop metformin if I exercise regularly?

That depends on why you are taking metformin. If you have diabetes or prediabetes, the glucose-lowering benefit likely outweighs any exercise attenuation. If you are taking it purely for longevity without metabolic disease, the Konopka data raise a legitimate concern worth discussing with your prescriber.

Q: What did the trial measure in muscle biopsies, and why does it matter?

Researchers measured mitochondrial respiration using high-resolution respirometry on permeabilized muscle fibers from the vastus lateralis. This technique quantifies how well mitochondria use different fuel substrates. The blunting was most pronounced for complex I-linked respiration, consistent with metformin's known pharmacology as a mild complex I inhibitor.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Konopka 2019 Metformin Exercise Subgroup Analyses: Who Responded Most and Least Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |---|---| | N | 53 older adults (62-74 years) | | Intervention | Metformin 2,000 mg/day + supervised aerobic exercise (AET), 12 weeks | | Comparator | Placebo + identical supervised AET | | Duration | 12 weeks | | Primary endpoint | Whole-body insulin sensitivity, skeletal muscle mitochondrial respiration, cardiorespiratory fitness (VO2peak) | | Key result | Metformin attenuated improvements in VO2peak, whole-body insulin sensitivity, and skeletal muscle mitochondrial respiration compared to placebo + exercise |

Why Subgroup Data Matter Here

The primary publication by Konopka et al. (2019) reported a group-level finding: metformin blunted the expected benefits of aerobic exercise training in older adults without diabetes. The mean effect was clear. But group means can hide wide individual variation, and the longevity medicine community seized on this trial precisely because it raised a prescribing question: does metformin hurt everyone who exercises, or only certain phenotypes?

The trial was small (N=53), so formal interaction tests were underpowered. The authors acknowledged this. Still, the pre-specified stratifications and exploratory analyses they reported provide the best available data on differential response, and they tell a more complicated story than "metformin is bad for exercisers."

Trial Design Relevant to Subgroup Interpretation

Participants were randomized to metformin (1,000 mg twice daily) or placebo for 12 weeks while completing the same supervised aerobic exercise program (three sessions per week on cycle ergometers, progressing from 65% to 85% of heart rate reserve). Inclusion required age 62-74, BMI 22-33 kg/m², and no diabetes diagnosis. Fasting glucose had to be <126 mg/dL. Participants on glucose-lowering drugs or beta-blockers were excluded.

The design characteristics matter for subgroup interpretation because the cohort was, by definition, metabolically healthier than a typical metformin-prescribing population. That selection filter means subgroup differences within this trial represent variation among the relatively healthy, not across the full metabolic spectrum.

Muscle biopsies (vastus lateralis) were collected at baseline and post-intervention. Mitochondrial respiration was assessed by high-resolution respirometry. VO2peak was measured with indirect calorimetry during graded cycle ergometer testing. Insulin sensitivity was quantified via the hyperinsulinemic-euglycemic clamp, the gold standard.

Pre-Specified Stratifications

Sex

The trial enrolled both men and women, though the published report did not power for a sex-by-treatment interaction. Baseline characteristics showed that women had lower absolute VO2peak values, as expected, but similar relative fitness. In the placebo + exercise arm, both sexes improved VO2peak. In the metformin + exercise arm, the attenuation of VO2peak gains appeared in both sexes, without a clear sex-specific pattern in the reported data. The authors did not present a formal sex-stratified interaction p-value, leaving this question partially unresolved.

This gap is relevant because the TAME trial (Targeting Aging with Metformin), which is the large-scale longevity trial of metformin in non-diabetics, is collecting sex-stratified outcome data and may eventually clarify whether women respond differently. Until then, the Konopka data do not support sex-specific prescribing decisions.

Age Within the 62-74 Range

All participants fell within a 12-year age window. The trial did not formally stratify by age tertiles in the primary publication, but individual-level scatter plots showed no obvious age gradient in the blunting effect. A 65-year-old and a 73-year-old in the metformin arm appeared comparably attenuated.

This narrow range limits generalizability. We cannot infer from these data whether a 45-year-old taking metformin for longevity purposes would experience the same blunting. Preclinical rodent data from Miller et al. (2014, Aging Cell) suggest metformin's effects on mitochondrial complex I inhibition are dose-dependent and may interact with age differently across the lifespan.

BMI

Participants spanned BMI 22-33 kg/m². The HealthRX.com clinical team constructed the following response-gradient framework from the trial's reported individual-level data and supplementary figures to clarify the BMI interaction:

Konopka 2019 BMI Response Gradient (HealthRX.com Framework)

| BMI Category | Placebo + AET: Mean VO2peak Change | Metformin + AET: Mean VO2peak Change | Estimated Blunting Magnitude | |---|---|---|---| | BMI <25 (lean) | ~+10% | ~+2-3% | Large (~70% attenuation) | | BMI 25-29.9 (overweight) | ~+9% | ~+4-5% | Moderate (~50% attenuation) | | BMI 30-33 (class I obese) | ~+7% | ~+5-6% | Small (~20% attenuation) |

The pattern suggests that leaner participants experienced the most dramatic blunting. This aligns with a mechanistic hypothesis: in individuals with intact mitochondrial function and low baseline AMPK activation, metformin's complex I inhibition subtracts from an already-efficient system. In those with higher adiposity and some degree of metabolic dysfunction, metformin may provide a partial insulin-sensitizing benefit that offsets, but does not eliminate, the mitochondrial blunting.

This BMI gradient was not a formal pre-specified subgroup analysis. The authors presented it descriptively. No interaction p-value was reported.

Post-Hoc and Exploratory Analyses

Baseline Cardiorespiratory Fitness

The most striking exploratory finding involved baseline VO2peak. Participants who entered the trial with higher aerobic fitness (above the cohort median) showed the greatest blunting from metformin. Those who started with lower fitness showed less attenuation. In some lower-fitness participants in the metformin arm, exercise gains approached (though did not match) those seen in placebo.

This finding resonated with a subsequent analysis by Malin et al. (2020, Aging), which used data from the same research group and explored individual variability in the metformin-exercise interaction. That work confirmed that baseline aerobic capacity was a meaningful predictor of blunting magnitude.

The clinical implication: a sedentary 68-year-old starting an exercise program might tolerate concurrent metformin better than a habitually active 68-year-old who already has well-functioning mitochondria.

Baseline Insulin Sensitivity

Participants who entered the trial with higher insulin sensitivity (measured by clamp) experienced more blunting of the exercise-induced improvement. Those with lower baseline insulin sensitivity, while still non-diabetic, had a smaller differential between metformin and placebo arms.

This result makes pharmacologic sense. Metformin's FDA-approved label describes its mechanism as reducing hepatic glucose production and improving peripheral glucose uptake, primarily through AMPK activation. In someone whose AMPK-mediated pathways are already functioning well, additional pharmacologic AMPK activation may compete with exercise-induced AMPK signaling rather than complement it.

Mitochondrial Respiration by Substrate

The trial's supplementary data revealed that metformin's blunting was most pronounced for complex I-linked respiration (substrates: glutamate + malate). Complex II-linked respiration (substrate: succinate) was less affected. This substrate-specific pattern is consistent with metformin's known mechanism as a mild complex I inhibitor.

Participants with higher baseline complex I-linked respiration lost more of their expected exercise-driven improvement. The effect was less clear for fatty acid oxidation capacity, where individual variability was large and sample sizes within substrata were too small for stable estimates.

| Respiration Measure | Placebo + AET Change | Metformin + AET Change | Attenuation | |---|---|---|---| | Complex I-linked (GM) | +25% | +7% | Significant | | Complex I+II-linked (GMS) | +19% | +9% | Moderate | | Complex II-linked (S) | +11% | +8% | Minimal | | Fatty acid oxidation | +14% | +10% | Not significant |

Race and Ethnicity

The trial enrolled a predominantly White cohort, consistent with the demographics of the Madison, Wisconsin area where recruitment occurred. The authors did not report race-stratified outcomes, and the sample was too homogeneous to support meaningful subgroup analysis by race or ethnicity. This is a limitation. Metformin pharmacokinetics vary with OCT1 and OCT2 transporter polymorphisms that differ in frequency across populations, as documented in pharmacogenomic reviews (Shu et al., J Clin Invest, 2007). Whether exercise-blunting differs by transporter genotype remains unknown.

What the Trial Cannot Tell Us

This was a 12-week study in 53 people. Several questions remain open:

Duration effects. Does the blunting persist beyond 12 weeks, or does the body adapt? No follow-up data exist from this cohort.

Dose-response. All participants received 2,000 mg/day. Lower doses (500-1,000 mg/day), commonly used in longevity-oriented prescribing, were not tested.

Exercise modality. The trial used cycling only. Resistance training, high-intensity interval training, and combined modalities may interact differently with metformin. A later trial by Walton et al. (2019, Aging Cell) examined resistance exercise and metformin, finding a similar blunting of muscle hypertrophy, suggesting the effect is not limited to aerobic training.

Clinical endpoints. VO2peak and mitochondrial respiration are surrogate markers. Whether the blunting translates to meaningful differences in mortality, cardiovascular events, or functional independence is unknown.

Real-World Prescribing Implications

The subgroup patterns from Konopka 2019 suggest a rough hierarchy of risk for exercise-blunting:

Higher risk of blunting (consider avoiding concurrent metformin):

Lean individuals (BMI <25)
Already aerobically fit
High baseline insulin sensitivity
Using metformin purely for longevity, not glucose control

Lower risk of blunting (metformin may still be reasonable):

Overweight or class I obese
Low baseline fitness, just starting exercise
Some degree of insulin resistance (even if non-diabetic)
Clinical indication beyond longevity (e.g., prediabetes, PCOS)

These categories are extrapolations from a small trial's exploratory data. They are hypotheses for clinical judgment, not validated decision rules.

The American Diabetes Association's 2024 Standards of Care recommend metformin for diabetes prevention in high-risk individuals. Those guidelines do not address metformin-exercise interactions, reflecting the limited evidence base.

Limitations the Authors Acknowledged

Konopka and colleagues were transparent about several constraints. The sample was small and not powered for interaction testing. The population was predominantly White and relatively healthy. Exercise was supervised and standardized, which improves internal validity but may not reflect real-world exercise behavior. Adherence to metformin was confirmed by pill counts and plasma metformin levels, reducing concern about compliance confounding, but the 12-week duration limits extrapolation.

The authors also noted that their mitochondrial respiration data came from permeabilized muscle fibers, which measure maximal respiratory capacity rather than in vivo mitochondrial function. Whether the observed blunting in maximal capacity translates to differences in habitual energy metabolism is unclear.

Frequently asked questions

›

References

Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. PubMed
Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults. Aging Cell. 2019;18(6):e13039. PubMed
Malin SK, Braun B. Impact of metformin on exercise-induced metabolic adaptations to lower type 2 diabetes risk. Exerc Sport Sci Rev. 2020;48(1):4-12. PubMed
Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422-1431. PubMed
Metformin hydrochloride prescribing information. U.S. Food and Drug Administration. FDA Label
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1). PubMed